ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Company Progress: ENDRA Life Sciences Inc. has accelerated enrollment in its global pilot study for the TAEUS system, leveraging AI and machine learning to enhance data accuracy and ease of use, while also reducing operating expenses by 54% year-over-year.
Financial Results: The company reported a net loss of $2.4 million for Q3 2024, down from $3.1 million in the same quarter last year, with significant reductions in operating expenses primarily due to cost-cutting measures and restructuring efforts.
Trade with 70% Backtested Accuracy
Analyst Views on NDRA
About NDRA
About the author
Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
ENDRA Launches Low-Cost TAEUS Liver Detection Technology Under $200
- Technology Validation: ENDRA's TAEUS device demonstrates a 100% PPV and 94% NPV at liver fat fraction thresholds of 12-22%, with an accuracy of 95%, showcasing its potential in clinical decision-making by effectively distinguishing between mild and severe steatosis patients.
- Cost Advantage: With an anticipated cost of under $200, TAEUS offers a significant reduction compared to the $2,500 MRI-PDFF exams, enabling frequent monitoring every eight weeks, thus lowering the high screening costs associated with drug development.
- Market Opportunity: As over 50 MASLD/MASH and 250 GLP-1 trials are ongoing globally, TAEUS's high accuracy and low cost position it as an ideal choice for drug developers and payors, significantly reducing overall clinical trial costs.
- Strategic Pathway: ENDRA plans to engage with the FDA in 2026 to align on clinical decision thresholds in multicenter studies, further advancing TAEUS's market application and regulatory approval.
ENDRA Life Sciences Reveals At-Market Private Placement Opportunity of Up to $14.4 Million
Private Placement Announcement: ENDRA Life Sciences has secured $4.9 million in commitments for a private placement, involving the sale of 744,340 shares of common stock and warrants for an additional 1.48 million shares.
Use of Proceeds and Advisory Board Addition: The company plans to use the majority of the net proceeds to establish its DAT operations and accumulate cryptocurrency, while also adding Jeff Dorman to its Digital Asset Advisory Board.
Ascendiant Capital Reaffirms Buy Rating on ENDRA Life Sciences, Adjusts Price Target to $38
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Community: Joining Benzinga Pro connects traders with over 10,000 serious market participants and provides access to exclusive stories and insights from Benzinga reporters.
Gold Falls 1%; ProKidney Shares Spike Higher
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones dropping over 150 points, while energy shares rose by 2.1%. Notable stock movements included ENDRA Life Sciences surging 134% and ProKidney Corp gaining 218%, while Sunrun Inc. fell 11% due to policy changes affecting clean-energy tax credits.
International Market Trends: European and Asian markets closed higher, with significant gains in indices such as the eurozone's STOXX 600 and Japan's Nikkei. Additionally, the U.S. Manheim Used Vehicle Value Index increased by 1.6% month-over-month for June, indicating a recovery following a decline in May.
US Stocks Mixed; Small Business Sentiment Falls In June
Market Overview: U.S. stocks showed mixed performance with the Dow Jones falling 0.22%, while NASDAQ gained slightly. The NFIB Small Business Optimism Index decreased to 98.6 in June, indicating a decline in small business sentiment.
Sector Performance: Energy shares rose by 1%, while utilities stocks fell by 1.5%. Notable stock movements included ENDRA Life Sciences Inc. surging 159% after a patent announcement, while Skyline Builders Group saw a significant drop of 28%.
Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
ENDRA Launches Low-Cost TAEUS Liver Detection Technology Under $200
- Technology Validation: ENDRA's TAEUS device demonstrates a 100% PPV and 94% NPV at liver fat fraction thresholds of 12-22%, with an accuracy of 95%, showcasing its potential in clinical decision-making by effectively distinguishing between mild and severe steatosis patients.
- Cost Advantage: With an anticipated cost of under $200, TAEUS offers a significant reduction compared to the $2,500 MRI-PDFF exams, enabling frequent monitoring every eight weeks, thus lowering the high screening costs associated with drug development.
- Market Opportunity: As over 50 MASLD/MASH and 250 GLP-1 trials are ongoing globally, TAEUS's high accuracy and low cost position it as an ideal choice for drug developers and payors, significantly reducing overall clinical trial costs.
- Strategic Pathway: ENDRA plans to engage with the FDA in 2026 to align on clinical decision thresholds in multicenter studies, further advancing TAEUS's market application and regulatory approval.
ENDRA Life Sciences Reveals At-Market Private Placement Opportunity of Up to $14.4 Million
Private Placement Announcement: ENDRA Life Sciences has secured $4.9 million in commitments for a private placement, involving the sale of 744,340 shares of common stock and warrants for an additional 1.48 million shares.
Use of Proceeds and Advisory Board Addition: The company plans to use the majority of the net proceeds to establish its DAT operations and accumulate cryptocurrency, while also adding Jeff Dorman to its Digital Asset Advisory Board.
Ascendiant Capital Reaffirms Buy Rating on ENDRA Life Sciences, Adjusts Price Target to $38
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Community: Joining Benzinga Pro connects traders with over 10,000 serious market participants and provides access to exclusive stories and insights from Benzinga reporters.
Gold Falls 1%; ProKidney Shares Spike Higher
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones dropping over 150 points, while energy shares rose by 2.1%. Notable stock movements included ENDRA Life Sciences surging 134% and ProKidney Corp gaining 218%, while Sunrun Inc. fell 11% due to policy changes affecting clean-energy tax credits.
International Market Trends: European and Asian markets closed higher, with significant gains in indices such as the eurozone's STOXX 600 and Japan's Nikkei. Additionally, the U.S. Manheim Used Vehicle Value Index increased by 1.6% month-over-month for June, indicating a recovery following a decline in May.
US Stocks Mixed; Small Business Sentiment Falls In June
Market Overview: U.S. stocks showed mixed performance with the Dow Jones falling 0.22%, while NASDAQ gained slightly. The NFIB Small Business Optimism Index decreased to 98.6 in June, indicating a decline in small business sentiment.
Sector Performance: Energy shares rose by 1%, while utilities stocks fell by 1.5%. Notable stock movements included ENDRA Life Sciences Inc. surging 159% after a patent announcement, while Skyline Builders Group saw a significant drop of 28%.
